

---

## Agenda Item H.1

### Report on material decisions of the Regulatory and Professional Policy Committee

---

From: Rory O'Donnell, Chair of the Regulatory and Professional Policy Committee

The Regulatory and Professional Policy Committee met on Thursday, 28 November 2024, at 10 am. The meeting was held in hybrid format, in PSI House and online via Microsoft Teams.

The agenda items below refer to the matters before Council for decision.

The full agenda for the meeting can be found in Annex 1, which highlights additional items discussed and items for information only.

### Agenda Item E – Operationalisation of Third Country Qualification Recognition (TCQR) Route

The Committee discussed proposed amendments to the Third Country Qualification Recognition (TCQR) Implementation Policy and the Pharmaceutical Society of Ireland (Fees) Rules 2014 to 2020 ('Fees Rules'). The Committee heard that the proposed revisions to the policy had been guided by legal engagement and advice. The proposed draft amending Fees rules had also been subject to legal scrutiny in drafting.

The Committee discussed the draft amendments to both the policy and the rules, including fees, procurement and the wider legislative framework. The Committee heard that the Executive had commenced the market-sounding exercise with potential vendors as part of the procurement process for the examination required under Path B.

**The Committee is recommending that Council**

- 1) approve the draft amendments to the TCQR Implementation Policy and recommend the policy to Council for approval, and**
- 2) recommend the approval of the Fees Rules to the Council to issue for Public Consultation.**

## Agenda Item F.1 – Consideration of proposed changes to PSI (Registration) and PSI (CPD) Rules (Drafts for Public Consultation)

The Committee was asked to consider proposed changes to the Pharmaceutical Society of Ireland (Continuing Professional Development) and Pharmaceutical Society of Ireland (Registration) rules.

The Committee heard that the draft rules were developed to reflect the policy changes previously approved by PSI Council in respect of the Continuing Professional Development (CPD) model for Pharmacists and the development and implementation of a CPD Model for Pharmaceutical Assistants.

The Committee was informed that a considerable preliminary consultation and engagement process had been carried out with key stakeholders including the RPP Committee prior to further legal drafting, in advance of a wider public consultation on the proposed draft rules.

The Committee discussed the draft rules, seeking further information on how CPD changes would be communicated with registrants.

**The Committee is recommending that the draft rules be approved by Council at its December meeting for public consultation in January 2025.**

## Agenda Item M.2 – Draft IOP Annual Workplan 2025

The Committee considered the draft IOP Annual Workplan 2025, having heard that as part of the development of the draft workplan PSI had carried out a prioritisation exercise following engagement with registrants and a number of other key stakeholders.

**The Committee is recommending that the draft IOP Annual Workplan 2025 be approved by Council.**

## Agenda Item M.3 – Suspension of Practice Review 2025

The Committee considered the implications of continuing to suspend Practice Review for 2025 while work is progressed on approval of the required changes to both the Pharmaceutical Society of Ireland (Continuing Professional Development) Rules and the Pharmaceutical Society of Ireland (Registration) Rules.

As outlined in Agenda Item F.1 above, these draft changes are intended to operationalise Council approved changes to the CPD model for pharmacists and the development and implementation of a CPD model for pharmaceutical assistants.

The Committee was reminded that in January, PSI Council decided to suspend Practice Review for 2024 pending further review, in line with recommendations of the review of the CPD model for pharmacists.

**The Committee is advising Council that Practice Review should continue to be suspended for 2025, pending implementation of the necessary changes to the Pharmaceutical Society of Ireland (Continuing Professional Development) and Pharmaceutical Society of Ireland (Registration) Rules.**

## Annex 1



**Agenda for PSI Regulatory and Professional Policy Committee  
held on 28 November 2024 at 10am.**

**The meeting will be in hybrid format held at PSI House and on Microsoft Teams.**

**Colour code: Red—for decision; Green—for discussion; Blue—for information**

Agenda Notation: \* - document provided in advance; \*\* - will be presented in slide deck at meeting;  
\*\*\* - verbal update

Indicative time	Item and descriptor		Presenter
10.00	A	Apologies	Chair
10.02	B	Declaration of Interests (See appendix A below)	Chair
10.03	C	Approval of Meeting Agenda*	Chair
10.04	D	Approval of Minutes – 12 September 2024 meeting*	Chair
10.05 – 25 mins	E	Operationalisation of Third Country Qualification Recognition Route  Update on TCQR process including the following decision items:	D Gaughan L Irwin
	E.1	Amendment to the TCQR Implementation Policy*	
	E.2	Draft PSI Fee Rules to support the revised process for TCQR* (Draft for Public Consultation)	
	E.3	Project Health Card Update*	
10.20	F	Continuing Professional Development System for Pharmacists	C O'Connell P Corbett
	F.1	Consideration of proposed changes to PSI (Registration) and PSI (CPD) Rules* (Drafts for Public Consultation)*	
	F.2	Project Health Card Update*	

10.40	G	Expert Taskforce	D Burns O Carroll
	G.1	Progress update***	
	G.2	Project Health Card update*	
10.50	H	Hospital Pharmacy Regulation	D Gaughan O Carroll
	H.1	Progress Update***	
11.00	I	Advance reform of the Pharmacy Act	D Burns R Duffy
	I.1	Progress update***	
	I.2	Project Health card update*	
11.15	J	MPharm Programme	C O'Connell A Boland
	J.1	Update on Accreditation Processes***	
11.25	K	Open Disclosure Project  Open Disclosure Project**	C O'Connell L Hamra
11.40	L	Emerging Risks to Future Pharmacy Workforce	C O'Connell L Hamra
	L.1	Project Health card update(*) ***	
11.45	M	IIOF Updates	C O'Connell P Corbett
	M.1	Quarterly update on IIOF operations and developments*	
	M.2	Draft IIOF Annual Workplan 2025*	
	M.3	Suspension of Practice Review 2025*	
12.00	N	iNAP2	D Burns R Duffy
	N.1	Update on our actions to contribute to Ireland's second National Action Plan on Antimicrobial Resistance 2021-2025***	
12.15	O	Patient and public involvement in our work	D Burns R Duffy
	O.1	Progress update***	
12.30	P	2024 Work Plan Projects – Project Health Cards	
	P.1	Project Health Card Update: Implementation of Policy Developments Relating to Pharmacy*	D Burns/R Duffy
	P.2	Project Health Card Update: Development of CPD Model for	A Boland

	P.3	Pharmaceutical Assistants* Project Health Card Update: Patient Safety and Quality Initiatives*	D Gaughan
12.35	Q	Service Planning Service Plan 2025*	J Kissane D Burns
12.45	R	Annual Committee Performance Review***	Chair
12.50	S	Terms of Reference RPP Committee Terms of Reference*	Chair
12.55	T	Proposed meeting dates for 2025: <ul style="list-style-type: none"> <li>• Thursday, 20 February</li> <li>• Thursday, 10 April</li> <li>• Thursday, 12 June</li> <li>• Thursday, 18 September</li> <li>• Thursday, 27 November</li> </ul> <p style="text-align: center;">AOB -Meeting close-</p>	Chair

*We anticipate the meeting should end at approximately 1pm.  
Rory O'Donnell, Chair of the Regulatory and Professional Policy Committee*

## APPENDIX A

### **Pharmacy Act 2007 Schedule 1, Section 9: Disclosure of certain interests**

9. (1) In this paragraph— “connected relative”, in relation to a person, means a spouse, a man and woman who are not married to each other but are cohabiting as husband and wife, parent, brother, sister, child or spouse of a child of the person;

“meeting” means a meeting of the Council or of a committee of the Council;

“member” includes a member of a committee of the Council;

“specified matter” means—

- (a) an arrangement to which the Council is a party or a proposed such arrangement, or
- (b) a contract or other agreement with the Council or a proposed such contract or agreement.

(2) A member present at a meeting where a specified matter arises who, otherwise than in his or her capacity as a member, has an interest in that matter—

- (a) shall at the meeting, disclose that fact and the extent of the interest,
- (b) may not influence or seek to influence a decision to be made in relation to the matter,
- (c) shall absent himself or herself from the meeting or that part of the meeting during which the matter is being discussed,
- (d) may not vote on a decision relating to the matter, and
- (e) may not take part in any further deliberation of the Council or any of its committees relating to the matter.

(3) For the purposes of this paragraph, but without prejudice to the generality of *subparagraph (2)*, a member shall be regarded as having an interest in a matter if a connected relative of that member or a nominee of either of them has such an interest.

(4) The disclosure shall be recorded in the minutes of the meeting and, for as long as the specified matter is being dealt with by the meeting, the member making the disclosure may not be counted for the purposes of determining the presence of a quorum for the meeting.

(5) The question of whether a member’s course of conduct, is or would be a contravention of *subparagraph (2)* shall be determined by the chair, whose decision shall be final, and the particulars of the determination shall be recorded in the minutes of the meeting.

(6) Where the member referred to in *subparagraph (4)* is the chair, the meeting shall choose another member to chair it for the purposes of the determination.

(7) If satisfied that a member has contravened *subparagraph (2)*, the Minister may remove the member from office and that person is then disqualified from office.